相关实验视频

Updated: Sep 13, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

新辅助性免疫检查点抑制改善了对肝脏黑色素瘤转移的保护

Sebastian A Wohlfeil¹, Céline Weller², Bianca Dietsch²

¹Department of Dermatology, Venereology, and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, and Center of Excellence in Dermatology, Mannheim, Germany; Section of Clinical and Molecular Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.

|July 27, 2025

概括

新辅助性免疫检查点抑制 (ICI) 通过促进抗瘤T_H1免疫反应,防止治疗耐药性,提供对皮肤黑色素瘤 (CM) 肝转移的优越保护.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
黑色素瘤研究黑色素瘤研究

背景情况:

具有肝转移的皮肤黑色素瘤 (CM) 对免疫检查点抑制 (ICI) 的反应不佳.
研究新辅助性ICI以预防肝转移和治疗耐药性至关重要.

研究的目的:

评估新辅助性ICI在预防CM肝转移中的有效性.
了解新辅助剂ICI的保护作用背后的免疫机制.

主要方法:

使用CM细胞建立了肝脏黑色素瘤转移的小鼠模型.
联合ICI (抗PD-1/抗CTLA-4) 在新辅助剂和辅助剂设置中进行.
通过scRNA-Seq,流细胞计和细胞因子检测分析了免疫细胞组成和反应.

主要成果:

与辅助疗法相比,新辅助ICI显著改善了对肝转移的保护.
新辅助性ICI导致瘤,血液和肝脏中的T细胞扩张,转向T_H1标志物.
在新辅助性ICI后,在肝脏中观察到降低的T_H2相关细胞因子 (IL-4,IL-15).

结论:

新辅助性ICI提供了对肝脏黑色素瘤转移的优越保护.
这种保护是通过转向抗瘤T_H1免疫反应来调节的.
新辅助性ICI是一种有前途的策略,用于预防CM的器官特异性治疗耐药性.

更多相关视频

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.